Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

differentiated thyroid carcinoma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

differentiated thyroid carcinoma

MONDO:0015447

Also known as:differentiated thyroid cancerdifferentiated thyroid gland cancerdifferentiated thyroid gland carcinoma

Find Clinical TrialsTrials

Overview

Differentiated thyroid carcinoma (DTC), also known as papillary or follicular thyroid carcinoma, is a slow-growing malignancy usually presenting in adults as an asymptomatic thyroid mass.

Treatments2 FDA approved

Clinical Trials74 registered · 25 recruiting

Diagnosis

Biomarker and diagnostic research for differentiated thyroid carcinoma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for differentiated thyroid carcinoma, including LEVOTHYROXINE SODIUM (LEVOXYL, approved 2001) and LIOTHYRONINE SODIUM (CYTOMEL, approved 1956).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

74 clinical trials registered, 25 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 8 PHASE3, 26 PHASE2, 7 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06860971](https://clinicaltrials.gov/study/NCT06860971)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 2:11 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:146

GARD

Genetic and Rare Diseases Info Center

GARD:12027

Questions for Your Care Team

→What are the benefits and potential side effects of LEVOXYL for managing differentiated thyroid carcinoma?
→Are any of the 74 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	71	27%
Disease patterns and progression	65	25%
Testing and diagnosis research	45	17%
Clinical study results	29	11%
Patient case studies	23	9%
Laboratory research	21	8%
New treatment approaches	5	2%
Other research	2	1%

Kisho

differentiated thyroid carcinoma

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

[⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study.

Less is more? Evaluating the role of radioiodine therapy in pediatric differentiated thyroid cancer management.

Locoregional recurrence after transaxillary robotic thyroidectomy for differentiated thyroid cancer: long-term outcomes in 10,504 patients.

differentiated thyroid carcinoma

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

[⁶⁸Ga]Ga-CTR-FAPI versus [⁶⁸Ga]Ga-FAPI-04 PET/CT for patient evaluation in radioiodine-refractory differentiated thyroid cancer: A prospective comparative study.

Less is more? Evaluating the role of radioiodine therapy in pediatric differentiated thyroid cancer management.

Locoregional recurrence after transaxillary robotic thyroidectomy for differentiated thyroid cancer: long-term outcomes in 10,504 patients.